CoStar Group, Inc. Announces $750M Public Offering Of Common Stock In Conjunction With Inclusion Into S&P 500 Index
CoStar Group, Inc. (NASDAQ:CSGP) ("CoStar"), a leading provider of online real estate marketplaces, information and analytics, announced today that in conjunction with the September 2, 2022 announcement by
Li-Cycle Holdings Q3 Revenue From Product Sales And Recycling Services $5.4M
Li-Cycle Holdings Corp. (NYSE:LICY) ("Li-Cycle" or the "Company"), an industry leader in lithium-ion battery resource recovery and the leading lithium-ion battery recycler in North America, today
Coda Octopus Group Q3 Sales $6.27M Up From $5.83M YoY
Coda Octopus Group (NASDAQ:CODA) reported $6.27 million in sales this quarter. This is a 7.60 percent increase over sales of $5.83 million the same period last year.
Aditxt Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening On September 14, 2022
Aditxt, Inc. (NASDAQ:ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, announced today that it will effect a 1-for-50 reverse split of
Taboola Announces 6% Workforce Reduction, $23M Cut In Discretionary Expenses And $15M Reduction In Capex; Expects To Reduce 2023 Operating Expenses By $50M
Realigning and restructuring teams to focus on three top priorities: performance advertising, e-Commerce and header bidding
Expect to reduce 2023 Operating Expenses by $50M, further improving Adjusted
Radiant Logistics Q4 EPS $0.40 Up From $0.20 YoY, Sales $398.61M Up From $257.91M YoY
Radiant Logistics (AMEX: RLGT) reported quarterly earnings of $0.40 per share. This is a 100 percent increase over earnings of $0.20 per share from the same period last year. The company reported $398.61 million in sales this quarter. This is a 54.55 percent increase over sales of $257.91 million the same period last year.
Edgewise Therapeutics Announces Proposed $100M Offering Of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ:EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common
Oramed Reports Top-Line Results From Phase 2 NASH Trial With Its ORMD-0801, Oral Insulin Candidate; Met Primary And Secondary Endpoint
Primary endpoint met: ORMD-0801 was safe and well tolerated
Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks
Strong evidence for treatment of NASH using